Su Yan-Jun, Ren Kai, Li Hui, Ren Xiu-Bao, Wang Chang-Li
Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
Zhonghua Zhong Liu Za Zhi. 2007 Dec;29(12):922-6.
To evaluate the distribution of CD4+ CD25+ regulatory T-cells (T-regs) in tumor-draining lymph nodes (TDLN) in patients with non-small cell lung caner (NSCLC), and to investigate the effect of CD4+ CD25+ T regulatory cells on the immune status of TDLN and the progression of NSCLC.
Regional tumor-draining lymph nodes of 53 NSCLC patients were resected during the operation. The percentage of CD4+ CD25+ T-regs as a subset of CD4+ T cells and CD8+ T cells were detected by immunofluorescence and regular immunohistochemistry, respectively. The level of cytokines TGF-beta1 and IL-10 was detected by real time quantitative RT-PCR.
CD4+ CD25+ T-regs in tumor-infiltrating lymph nodes from the patients with NSCLC accounted for 28.80% +/- 8.06% of total CD4+ T cells, and were significantly increased comparing with that (15.48% +/- 4.66%) in the tumor-free lymph nodes (P < 0.01). The percentage of CD4+ CD25+ T-regs in TDLN of NSCLC patients was negatively correlated with the amount of CD8+ T cells within the lymph nodes (r = -0. 756, P < 0.001), but positively correlated with the level of TGF-beta1 (r = 0.645, P < 0.001) and IL-10 (r = 0.769, P < 0.001). It also increased as NSCLC getting progressed, which was 30.42% +/- 7.47% in stage III versus 16.22% +/- 4.88% in stage I and III; 32.58% +/- 7.52% in N2 versus 22.76% +/- 4.67% in N1, with a significant difference between the two groups, respectively (P < 0.01).
The population of CD4+ CD25+ T regulatory cells in tumor-draining lymph nodes in patients with non-small cell lung caner is positively correlated with the progression and infiltration of lung cancer, which might provide new immunologic method to evaluate the progression and prognosis of non-small cell lung caner. The outcomes of biotherapy for NSCLC may be improved in the future through regulating the CD4+ CD25+ T regulatory cells.
评估非小细胞肺癌（NSCLC）患者肿瘤引流淋巴结（TDLN）中CD4+CD25+调节性T细胞（Tregs）的分布情况，并探讨CD4+CD25+T调节细胞对TDLN免疫状态及NSCLC进展的影响。
手术中切除53例NSCLC患者的区域肿瘤引流淋巴结。分别采用免疫荧光法和常规免疫组化法检测CD4+CD25+Tregs作为CD4+T细胞和CD8+T细胞亚群的百分比。采用实时定量RT-PCR检测细胞因子TGF-β1和IL-10的水平。
NSCLC患者肿瘤浸润淋巴结中CD~(4+)CD25+Tregs占CD4+T细胞总数的28.80%±8.06%，与无肿瘤淋巴结中的（15.48%±4.66%）相比显著升高（P<0.01）。NSCLC患者TDLN中CD4+CD25+Tregs的百分比与淋巴结内CD8+T细胞数量呈负相关（r=-0.756，P<0.001），但与TGF-β1水平（r=0.645，P<0.001）和IL-10水平（r=0.769，P<0.001）呈正相关。随着NSCLC进展其也升高，Ⅲ期为30.42%±7.47%，而Ⅰ期和Ⅱ期为16.22%±4.88%；N2期为32.58%±7.52%，N1期为22.76%±4.67%，两组间差异均有统计学意义（P<0.01）。
非小细胞肺癌患者肿瘤引流淋巴结中CD4+CD25+T调节细胞数量与肺癌进展及浸润呈正相关，这可能为评估非小细胞肺癌的进展和预后提供新的免疫学方法。未来通过调节CD4+CD25+T调节细胞可能改善NSCLC生物治疗的效果。
